ArticlePloS one2019
Multifunctional graphene oxide/iron oxide nanoparticles for magnetic targeted drug delivery dual magnetic resonance/fluorescence imaging and cancer sensing.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 151 citations in OpenAlex.
- Magnetic Graphene Composites: From Rational Synthesis, Structural Design to Multifunctional Applications.Molecules (Basel, Switzerland) · 2026Review
- Next-generation nanomedicine for cancer therapy: advances, challenges, and future perspectives.Frontiers in chemistry · 2026Review
- Synthesis of terbium and silica modified graphene quantum dots for targeted bioimaging of breast cancer cells using folate receptors.Scientific reports · 2025Article
- Sustainable Nanotechnology and Artificial Intelligence to Empower Image-Guided Therapy for Precision Healthcare.BME frontiers · 2025Review
- Nanocomposites Based on Iron Oxide and Carbonaceous Nanoparticles: From Synthesis to Their Biomedical Applications.Materials (Basel, Switzerland) · 2024Review
- Functionalizing of magnetic nanoparticles as nano-architecture towards bioimaging and colorimetric recognition of MCF-7 cells: dual opto-sensing and fluorescence monitoring for early-stage diagnosis of breast cancer.Mikrochimica acta · 2024Article
- Graphene-Oxide Peptide-Containing Materials for Biomedical Applications.International journal of molecular sciences · 2024Review
- Graphene-based hybrid composites for cancer diagnostic and therapy.Journal of translational medicine · 2024Review
- Review
- Graphene Oxide Nanoparticles and Organoids: A Prospective Advanced Model for Pancreatic Cancer Research.International journal of molecular sciences · 2024Review
- Application Research Progress of Nanomaterial Graphene and its Derivative Complexes in Tumor Diagnosis and Therapy.Current medicinal chemistry · 2024Review
- Revolutionizing Cancer Care: Advances in Carbon-Based Materials for Diagnosis and Treatment.Cureus · 2024Review
- Artificial Intelligence in Regenerative Medicine: Applications and Implications.Biomimetics (Basel, Switzerland) · 2023Review
- Doped Graphene Quantum Dots as Biocompatible Radical Scavenging Agents.Antioxidants (Basel, Switzerland) · 2023Article
- A Recent Review on Cancer Nanomedicine.Cancers · 2023Review
- The role of nanoparticles and nanomaterials in cancer diagnosis and treatment: a comprehensive review.American journal of cancer research · 2023Review
- Iron Oxide Nanoparticles: A Review on the Province of Its Compounds, Properties and Biological Applications.Materials (Basel, Switzerland) · 2022Review
- Dual-Mode Fluorescence/Ultrasound Imaging with Biocompatible Metal-Doped Graphene Quantum Dots.ACS biomaterials science & engineering · 2022Article
- SPIONs Conjugate Supported Anticancer Drug Doxorubicin's Delivery: Current Status, Challenges, and Prospects.Nanomaterials (Basel, Switzerland) · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graphene Oxide (GO) has recently attracted substantial attention in biomedical field as an effective platform for biological sensing, tissue scaffolds and in vitro fluorescence imaging. However, the targeting modality and the capability of its in vivo detection have not been explored. To enhance the functionality of GO, we combine it with superparamagnetic iron oxide nanoparticles (Fe3O4 NPs) serving as a biocompatible magnetic drug delivery addends and magnetic resonance contrast agent for MRI. Synthesized GO-Fe3O4 conjugates have an average size of 260 nm and show low cytotoxicity comparable to that of GO. Fe3O4 nanoparticles provide superparamagnetic properties for magnetic targeted drug delivery allowing simple manipulation by the magnetic field and magnetic resonance imaging with high r2/r1 relaxivity ratios of ~10.7. GO-Fe3O4 retains pH-sensing capabilities of GO used in this work to detect cancer versus healthy environments in vitro and exhibits fluorescence in the visible for bioimaging. As a drug delivery platform GO-Fe3O4 shows successful fluorescence-tracked transport of hydrophobic doxorubicin non-covalently conjugated to GO with substantial loading and 2.5-fold improved efficacy. As a result, we propose GO-Fe3O4 nanoparticles as a novel multifunctional magnetic targeted platform for high efficacy drug delivery traced in vitro by GO fluorescence and in vivo via MRI capable of optical cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.